Needham Reiterates Buy on NeoVolta, Maintains $8 Price Target
Needham analyst Sean Milligan reiterates NeoVolta (NASDAQ:NEOV) with a Buy and maintains $8 price target.
Filings · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Needham analyst Sean Milligan reiterates NeoVolta (NASDAQ:NEOV) with a Buy and maintains $8 price target.
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
NeoVolta shares tumble 16% after hours following fiscal 2026 results and wider annual loss.